Cite this: *RSC Adv.*, 2017, 7, 7259

Cytotoxic trichothecene-type sesquiterpenes from the sponge-derived fungus *Stachybotrys chartarum* with tyrosine kinase inhibition†

Yong Li,^a Dong Liu,^a Zhongbin Cheng,^a Peter Proksch^b and Wenhan Lin^{*a}

Bioassay-guided fractionation of the sponge (*Niphates recondite*)-associated fungus *Stachybotrys chartarum* revealed that the EtOAc fraction shows inhibitory effects against tumor cell lines. Chromatographic separation of the active fraction resulted in the isolation of 15 trichothecene-based sesquiterpenes, including four new compounds, namely chartarenes A–D (1–4). The structures of the new compounds were determined on the basis of extensive spectroscopic analysis and chemical conversion. Compounds 1–15 exerted potent or selective inhibition against a panel of tumor cell lines including HCT-116, HepG2, BGC-823, NCI-H1650, and A2780, with IC₅₀ values ranging from 10^{−2} to 10 μM. In addition, these compounds showed potent inhibition against tumor-related kinases FGFR3, IGF1R, PDGFRb, and TRKB.

Received 17th November 2016
Accepted 7th January 2017

DOI: 10.1039/c6ra26956g

www.rsc.org/advances

1. Introduction

Trichothecenes are a group of sesquiterpene-based mycotoxins,^{1–6} which are markedly cytotoxic toward eukaryotic organisms,⁷ including high phytotoxicity.^{8–10} The mechanism of toxicity is attributed to the inhibition of protein and DNA synthesis, and the mitochondrial electron transport system.^{11,12} Biogenetically, the mevalonate pathway is involved in the generation of this typical scaffold and chemically related derivatives such as apotrichothecene-type and sambucinol-type analogues.^{13,14} Apart from the phytotoxicity and mammalian intoxications, trichothecene-related compounds exhibited potent inhibitory effects for tumors,⁴ and diacetoxyscirpenol (anguidine) has even been developed for clinical trials as an anticancer agent.¹⁵ The structure–activity relationships revealed that the structural variety directly affects the cytotoxic activity, while destruction of the epoxide moiety and rearrangement of the ring system resulted in the virtual elimination of cytotoxicity.¹⁶ It was noted that a slight change in trichothecenes could dramatically reduce the toxicity but still retain the activity of apoptosis induction in human cancer cells, as exemplified by 2',3'-epoxymyrothecine A and myrothecine A inducing the apoptosis of tumor cell lines through the induction of PARP cleavage and JNK phosphorylation with low cytotoxicity.³ The derivatives of roridins A and H and verrucarins A and J exhibited

extraordinary activities *in vivo* against P388 mouse leukemia with high therapeutic index,^{17,18} and trichothecinol A strongly inhibited TPA-induced tumor promotion for cancer preventive activity.¹⁹ These findings suggested that trichothecenes are promising leads which are applicable for cancer chemotherapy. During our study on antitumor-active metabolites from marine-derived fungi, we found that the EtOAc extract of a rice solid cultured fungus, *Stachybotrys chartarum*, isolated from a sponge (*Niphates recondite*), showed significant cytotoxicity against a panel of tumor cell lines including HCT-116 and HepG2 with IC₅₀ values <10 μg mL^{−1}. This fungus was then subjected to large-scale fermentation, while chromatographic separation of the EtOAc fraction resulted in the isolation of 15 trichothecene-based sesquiterpenes (1–15) (Fig. 1).

2. Experimental section

2.1. General procedures

Optical rotations were measured with a Rudolph Autopol III automatic polarimeter. IR spectra were obtained with a Thermo Nicolet Nexus 470 FT-IR spectrometer. ¹H and ¹³C NMR, and 2D NMR spectra were recorded on Bruker Avance 400 NMR and Bruker Avance 500 NMR spectrometers (400/500 MHz for ¹H NMR and 100/125 MHz for ¹³C NMR, respectively). ESIMS and HRESIMS spectra were obtained with a Thermo Scientific LTQ Orbitrap XL instrument. Silica gels (160–200 and 200–300 mesh, Qingdao Marine Chemistry Co. Ltd) and ODS (50 μm, YMC) were used for column chromatography. Precoated silica gel plates (Merck, Kieselgel 60 F₂₅₄, 0.25 mm) were used for TLC analyses. HPLC was performed with an Alltech instrument (426-HPLC pump) equipped with an Alltech uvis-200 detector at 210 nm and semipreparative reversed-phased columns (YMC-packed C₈, 5 μm, 250 mm × 10 mm).

^aState Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100191, P. R. China. E-mail: whlin@bjmu.edu.cn; Fax: +86-10-82806188

^bInstitute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine University, 40225 Duesseldorf, Germany

† Electronic supplementary information (ESI) available. CCDC 1516457–1516459. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c6ra26956g

Fig. 1 Structures of 1–15.

2.2. Microorganism

The fungal strain WGC-25C-6 was isolated from the sponge *Niphates recondite*, which was collected from the inner coral reef at a depth of 10 m in Beibuwan Bay, Guangxi Province of P. R. China, in August 2010. The fungal strain was identified by comparing the morphological character and 18S rDNA sequence with those of standard records. Specifically, the morphological examination was performed by scrutinizing the fungal culture, the mechanism of spore production, and the characteristics of the spores. For inducing sporulation, the fungal strain was separately inoculated on PDA. All experiments and observations were repeated at least twice leading to the identification of the strain as *Stachybotrys chartarum*. The fungal strain WGC-25C-6 was deposited at the State Key Laboratory of Natural and Biomimetic Drugs, Peking University, China.

2.3. Fermentation

Large-scale fermentation was carried out in 30 Fernbach flasks (500 mL) each containing 80 g of rice. Distilled H₂O (120 mL) was added to each flask, and the contents were soaked overnight before autoclaving at 15 psi for 30 min. After cooling to room temperature, each flask was inoculated with 5.0 mL of the spore inoculum and incubated at 25 °C for 40 days.

2.4. Extraction and isolation

The fermented material was extracted successively with EtOAc (3 × 500 mL). The EtOAc layer was evaporated to dryness under vacuum to afford a crude extract (30 g).

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay results indicated that the EtOAc extract had significant inhibitory effects against the tumor cell lines HCT-116 (IC₅₀ < 10 µg mL⁻¹) and HepG2 (IC₅₀ < 10 µg mL⁻¹). The EtOAc fraction (10 g) was subjected to silica gel vacuum liquid chromatography, eluting with CH₂Cl₂–MeOH (gradient from 0 : 1 to 1 : 0) to obtain 10 fractions (FA–FJ). Additional MTT assay indicated that the fractions FA and FC–FJ showed weak cytotoxicity toward HCT-116 and HepG2 cell lines with IC₅₀ > 10 µg mL⁻¹, whereas the fraction FB exhibited inhibitory effects against HCT-116 and HepG2 cell lines with IC₅₀ < 5 µg mL⁻¹. FB (2.2 g) was fractionated on a silica gel column eluting with CH₂Cl₂–MeOH (from 100 : 0 to 100 : 5) to afford three subfractions (SB1–SB3). SB3 (412.2 mg) was separated by column chromatography on ODS gel eluting with H₂O–MeOH (from 1 : 1 to 0 : 1) to yield 2 (183.7 mg) and 3 (100.1 mg). Compounds 5 (199 mg), 4 (2.8 mg), 9 (5.3 mg), and 10 (9.0 mg) were purified from SB2 (325.5 mg) by semipreparative HPLC (C₁₈) with a mobile phase of MeOH–H₂O (4 : 1). FB2 (800 mg) was separated by column chromatography on silica gel (300 mesh) eluting with CH₂Cl₂–MeOH (50 : 1) to afford four

Table 1 ^1H NMR and ^{13}C NMR data of 1–3 (DMSO- d_6)

	1		2		3	
1	95.2 C		91.2 C		95.8 C	
2	37.0 CH ₂	1.95, m; 2.00, m	85.7 CH	3.48, dd ($J = 5.0$, 8.8 Hz)	80.2 CH	4.06, dd ($J = 2.0$, 4.8 Hz)
3	25.9 CH ₂	1.68, m; 1.65, m	36.9 CH ₂	1.47, m; 2.08, m	41.7 CH ₂	1.68, ddd ($J = 4.8$, 6.0, 16.0 Hz); 2.37, ddd ($J = 2.0$, 8.9, 16.0 Hz)
4	36.9 CH ₂	1.30, m; 2.00, m	69.2 CH	3.89, ddd ($J = 4.8$, 5.0, 8.0 Hz)	74.0 CH	3.91, ddd ($J = 6.0$, 6.4, 8.9 Hz)
5	56.1 C		57.6 C		54.9 C	
6	45.2 C		42.7 C		47.3 C	
7	27.5 CH ₂	1.36, ddd ($J = 4.4$, 5.0, 12.4 Hz); 1.52, ddd ($J = 3.0$, 12.0, 12.4 Hz)	25.0 CH ₂	1.06, m; 1.85, m	30.5 CH ₂	1.36, ddd ($J = 4.8$, 5.0, 12.8 Hz), 1.75, m
8	29.3 CH ₂	1.96, m	28.1 CH ₂	1.82, m; 1.96, m	28.8 CH ₂	1.92, ddd ($J = 3.0$, 4.8, 14.0 Hz); 2.10, m
9	134.7 C		139.4 C		143.9 C	
10	122.1 CH	5.47, brs	119.2 CH	5.44, d ($J = 3.2$ Hz)	117.5 CH	5.26, s
11	81.1 CH	4.12, brs	76.3 CH	3.62, d ($J = 3.2$ Hz)	107.1 C	
12	71.8 CH ₂	3.31, d ($J = 10.4$ Hz); 3.88, d ($J = 10.4$ Hz)	62.4 CH ₂	3.41, dd ($J = 6.0$, 12.0 Hz); 3.52, dd ($J = 6.0$, 12.0 Hz)	58.1 CH ₂	3.69, d ($J = 6.0$ Hz)
13	22.9 CH ₃	0.81, s	10.1 CH ₃	0.93, s	10.7 CH ₃	0.85, s
14	15.8 CH ₃	0.99, s	14.0 CH ₃	1.06, s	14.5 CH ₃	0.75, s
15	20.2 CH ₃	1.61, s	23.5 CH ₃	1.65, s	23.0 CH ₃	1.71, s
1'	101.9 CH	4.37, d ($J = 2.5$ Hz)				
2'	71.0 CH	3.62, dd ($J = 2.5$, 5.2 Hz)				
3'	74.2 CH	3.27, dd ($J = 5.2$, 7.0 Hz)				
4'	67.6 CH	3.23, t ($J = 7.0$ Hz)				
5'	78.0 CH	3.02, ddd ($J = 6.0$, 7.0, 10.0 Hz)				
6'	61.9 CH ₂	3.66, dd ($J = 6.0$, 12.0 Hz) 3.44, dd ($J = 10.0$, 12.0 Hz)				
OH-4				4.50, d ($J = 4.8$ Hz)		4.72, d ($J = 6.4$ Hz)
OH-12				3.90, t ($J = 6.0$ Hz)		4.98, t ($J = 6.0$ Hz)
OMe			58.2 CH ₃	3.26, s		

subfractions (FB2-1 to FB2-4). FB2-3 (344.6 mg) was purified by Sephadex LH-20 with CHCl_3 -MeOH (1 : 1) to yield **14** (8.9 mg), **8** (16.9 mg), **13** (20.7 mg), **15** (90.2 mg), **11** (19.5 mg), and **7** (13.9 mg). FB2-4 (142.4 mg) was chromatographed on an ODS column eluting with MeOH- H_2O (gradient from 1 : 1 to 1 : 0) to afford **12** (3.9 mg) and **6** (2.3 mg). FB2-2 (12.7 mg) was purified by semipreparative HPLC eluting with MeOH- H_2O (3 : 2) to yield **1** (4.2 mg).

Chartarene A (1). Colorless oil; $[\alpha]_{\text{D}}^{22} -19.9$ (c 0.43, MeOH); UV (MeOH) λ_{max} 347 nm; IR (KBr) γ_{max} 3387, 2928, 2866, 1770, 1758, 1575, 1453, 1374, 1241 cm^{-1} ; ^1H and ^{13}C NMR data, see Table 1; HRESIMS (m/z 421.2191 $[\text{M} + \text{Na}]^+$, calcd 421.2202 for $\text{C}_{21}\text{H}_{34}\text{O}_7\text{Na}$).

Chartarene B (2). White solid; mp 182.1–183.6 °C; $[\alpha]_{\text{D}}^{22} -118$ (c 0.05, MeOH); UV (MeOH) λ_{max} 204 nm; IR (KBr) γ_{max} 3381, 2966, 2933, 1450, 1376, 1245, 1092 cm^{-1} ; ^1H and ^{13}C NMR data, see Table 1; HRESIMS (m/z 283.3885 $[\text{M} + \text{H}]^+$, calcd 283.3880 for $\text{C}_{32}\text{H}_{53}\text{O}_8$).

Chartarene C (3). White solid; mp 206.1–207.6 °C; $[\alpha]_{\text{D}}^{22} -83.6$ (c 0.05, MeOH); UV (MeOH) λ_{max} 252 nm; IR (KBr) γ_{max} 3736, 3631, 2928, 2867, 1455, 1377, 1191, 1143 cm^{-1} ; ^1H and ^{13}C NMR data, see Table 1; HRESIMS (m/z 289.14168 $[\text{M} + \text{Na}]^+$, calcd 289.14103 for $\text{C}_{15}\text{H}_{22}\text{O}_4\text{Na}$).

Chartarene D (4). White solid; mp 223.1–224.6 °C; $[\alpha]_{\text{D}}^{22} -39.2$ (c 0.05, MeOH); UV (MeOH) λ_{max} 261 nm; IR (KBr) γ_{max} 3297, 2949, 1734, 1456, 1375, 1232, 1074 cm^{-1} ; ^1H and ^{13}C NMR data, see Table 1; HRESIMS (m/z 535.23084 $[\text{M} + \text{Na}]^+$, calcd 535.23024 for $\text{C}_{29}\text{H}_{36}\text{O}_8\text{Na}$).

Compound 14. White solid; mp 212.1–213.6 °C; $[\alpha]_{\text{D}}^{22} 20.4$ (c 0.05, MeOH); UV (MeOH) λ_{max} 204 nm; IR (KBr) γ_{max} 3386, 2945, 2871, 1375, 1246, 1047 cm^{-1} ; ^1H and ^{13}C NMR data, see Table 1; HRESIMS (m/z 269.1751 $[\text{M} + \text{H}]^+$, calcd 269.1753).

2.5. Acidic hydrolysis of 1

Compound **1** (2 mg) was dissolved in acetone (2 mL) and then was treated with 6 N HCl (1 mL) and heated at 90 °C for 12 h. The

mixture was dried under vacuum, and then dissolved in 5 mL H₂O. After extraction by EtOAc, the monosaccharide was treated with (+)-2-octanol (0.2 mL) in the presence of trifluoroacetic acid (1 drop) in a stoppered reaction vial at 130 °C overnight. The mixture was evaporated to dryness and acetylated with Ac₂O in pyridine. The acetylated (+)-2-octyl glycoside was analyzed by gas chromatography using corresponding authentic samples prepared from sugars. Comparison of the retention time of the sugar derivative derived from **1** (*T_R* = 19.18 min) with those of standard samples indicated the sugar of **1** to be in agreement with D-mannose.

2.6. X-ray crystallographic analysis

Crystal data were obtained with a Rigaku MicroMax 002+ single-crystal X-ray diffractometer. Cell parameter measurements and data collection were performed with a Bruker APEX2 CCD diffractometer using the wavelength for CuK α (λ = 1.5418 Å) radiation. Compounds were crystallized in polar space groups. The crystal structures of **3**, **6**, and **14** were solved by direct methods (SHELXS-97), and subsequent Fourier difference techniques (SHELXL-97, version 6.10, Bruker AXS Inc.). The crystallographic data for the structures of **3**, **6**, and **14** have been deposited with the Cambridge Crystallographic Data Centre (CCDC numbers: 1516457 for **3**, 1516459 for **6**, 1516458 for **14**).†

Colorless crystals of **3** were obtained from CH₂Cl₂/MeOH (1 : 1) using the vapor diffusion method. C₁₅H₂₂O₄ (*M* = 266.34 g mol^{−1}), orthorhombic, space group *P*₂₁2₁2₁, *a* = 6.4486(3) Å, *b* = 11.3707(10) Å, *c* = 17.7648(15) Å, α = 90°, β = 90°, γ = 90°, *V* = 1302.61(17) Å³, *Z* = 4, *T* = 98.8 K, μ (CuK α) = 0.792 mm^{−1}, *D*_{calc} = 1.3580 g cm^{−3}, reflections measured (9.24° ≤ 2 θ ≤ 143.6°), 2490 unique (*R*_{int} = 0.0191, *R*_{sigma} = 0.0324) which were used in all calculations. The final *R*₁ was 0.0404 (*I* > 2 σ (*I*)) and *wR*₂ was 0.1049 (all data). Flack parameter = 0.2(2).

Colorless crystals of **6** were obtained from MeOH. C₂₉H_{38.5}O_{11.25}·H₂O (*M* = 567.10 g mol^{−1}), monoclinic (0.40 × 0.35 × 0.35), space group *P*₂₁2₁2₁ (no. 4), *a* = 10.4204(3) Å, *b* = 13.0839(3) Å, *c* = 20.0354(7) Å, α = 90°, β = 90°, γ = 90°, *V* = 2731.60(14) Å³, *Z* = 4, *T* = 103(2) K, μ (CuK α) = 0.886 mm^{−1}, *D*_{calc} = 1.307 g cm^{−3}, reflections measured (8.08° ≤ 2 θ ≤ 143.52°), 5222 unique (*R*_{int} = 0.0176, *R*_{sigma} = *N/A*) which were used in all calculations. The final *R*₁ was 0.0351 (*I* > 2 σ (*I*)) and *wR*₂ was 0.0925 (all data). Flack parameter = −0.03(13).

Colorless crystals of **14** were obtained from acetone/MeOH (1 : 1). C₁₅H₂₄O₄ (*M* = 268.34 g mol^{−1}), orthorhombic (0.40 × 0.20 × 0.15), space group *P*₂₁2₁2₁, *a* = 6.96010(16) Å, *b* = 7.10939(15) Å, *c* = 27.6935(7) Å, α = 90°, β = 90°, γ = 90°, *V* = 1370.33(5) Å³, *Z* = 4, *T* = 101.5 K, μ (CuK α) = 0.753 mm^{−1}, *D*_{calc} = 1.301 g cm^{−3}, reflections measured (12.78° ≤ 2 θ ≤ 143.78°), 2610 unique (*R*_{int} = 0.0170, *R*_{sigma} = 0.02601) which were used in all calculations. The final *R*₁ was 0.0381 (*I* > 2 σ (*I*)) and *wR*₂ was 0.0980 (all data). Flack parameter = 0.01(16).

2.7. Cytotoxicity assay

Test samples were dissolved in dimethyl sulfoxide (DMSO) to make stock solutions and further diluted in culture medium upon assay. The cancer cell lines were cultured in RPMI 1640 medium, containing 10% fetal bovine serum. The cell lines were

maintained at 37 °C in a humidified environment containing 5% CO₂. To determine the effects of the compounds on cell viability, the cell number was quantified using a standard colorimetric MTT assay. Cells were plated in a 96-well plate (5 × 10³ cells per well) and allowed to attach overnight. Cells were treated with 1, 2, 4, 8, and 10 μM of each compound in culture medium for 72 h. Then, new culture medium was added with 20 μL of MTT (5 mg mL^{−1} stock in PBS) per well and incubated for 4 h at 37 °C. Finally, the culture medium was discarded, and 150 μL of DMSO was added per well to dissolve the purple formazan crystals. Absorbance of the solution was measured using a microplate reader spectrophotometer (Bio-Rad Laboratories, Inc., Hercules, CA, USA), at a wavelength of 490 nm. The absorbance of untreated cells in the medium (negative control) was 100%. Paclitaxel was used as a positive control and showed cytotoxic activity with IC₅₀ values of 0.03, 0.01, 0.01, 0.04, and 0.01 μM against the HCT-116, HepG2, BGC-823, NCI-H1650, and A2780 tumor cell lines, respectively. The compound with IC₅₀ < 1 μM was further screened by the diluted concentrations of 0.1, 0.2, 0.4, and 0.8 μM, while the compound with IC₅₀ < 0.1 μM was diluted to 0.01 μM for additional assay. The human malignant cell lines (colon carcinoma HCT-116, hepatocellular carcinoma HepG2, gastric carcinoma BGC-823, non-small cell lung carcinoma NCI-H1655, and ovarian carcinoma A2780) used in this study were purchased from the China Infrastructure of Cell Line Resources.

2.8. Anti-kinase assay

Assay for protein kinase inhibition was performed in 96-well Flash Plates from PerkinElmer/NEN (Boston, MA) in a 50 μL reaction volume. The reaction cocktail contained 20 μL of assay buffer, 5 μL of ATP solution (in H₂O), 5 μL of test compound (in 10% DMSO), 10 μL of substrate, and 10 μL of purified recombinant protein kinase. The assay for all enzymes contained 60 mM HEPES–NaOH (pH 7.5), 3 mM MgCl₂, 3 mM MnCl₂, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg mL^{−1} PEG 20000, and 1 μM [γ-33P]-ATP (*ca.* 5 × 10⁵ cpm per well). The human kinases FGFR3 (CD333), IGF1R (CD221), PDGFRb (CD140b), and TRKB (NTRK2) were obtained from Sino Biological Inc.

3. Results and discussion

3.1. Structure elucidation of new compounds

Chartarene A (**1**) has a molecular formula of C₂₁H₃₄O₇ as determined by HRESIMS and NMR data, containing five degrees of unsaturation. The ¹H NMR spectrum exhibited the resonances of three methyl singlets (δ_{H} 0.81, 0.99, 1.61), an olefinic proton at δ_{H} 5.47 (brs, H-10), as well as a number of alkyl protons and hydroxylated methine and methylene protons. The ¹³C NMR spectrum showed a total of 21 carbon resonances, including two olefinic carbons at δ_{C} 134.7 (C-9) and 122.1 (C-10) for a double bond. Based on the 2D NMR data analyses, an apotrichothecene nucleus²⁰ structurally related to apotrichodiol²¹ was established. This assignment was evidenced by the COSY correlations between H₂-7 (δ_{H} 1.36, 1.52)/H₂-8 (δ_{H}

Fig. 2 Key COSY and HMBC correlations of 1, 3 and 4.

Fig. 3 Key NOE correlations of 1 and 2.

1.96), H₂-3 (δ_{H} 1.65, 1.68) to H₂-2 (δ_{H} 1.95, 2.00) and H₂-4 (δ_{H} 1.30, 2.00), in addition to the HMBC interactions from H₃-15 (δ_{H} 1.61) to C-8 (δ_{C} 29.3), C-9 and C-10, H₃-14 (δ_{H} 0.99) to C-5 (δ_{C} 56.1), C-6 (δ_{C} 45.2), C-7 (δ_{C} 27.5), and C-11 (δ_{C} 81.1), H₃-13 (δ_{H} 0.81) to C-1 (δ_{C} 95.2), C-4 (δ_{C} 36.9), C-5 and C-6, and H₂-12 (δ_{H} 3.31, 3.88) to C-1, C-2 (δ_{C} 37.0), and C-5. The HMBC interaction between H-11 (δ_{H} 4.12) and C-1 clarified an ether bridge between C-1 and C-11 (Fig. 2). Thus, a tricyclic core with methyl substitution at C-5, C-6 and C-9 and an oxymethylene at C-1, as well as a double bond at C-9 and C-10 was deduced. The remaining six oxygenated carbons (δ_{C} 101.9, 78.0, 74.2, 71.0, 67.6, 61.9) were attributed to a sugar moiety. The J values ($J_{\text{H-3'}/\text{H-4'}} = 7.0$ Hz, $J_{\text{H-4'}/\text{H-5'}} = 7.0$ Hz, $J_{\text{H-3'}/\text{H-2'}} = 2.5$ Hz) in association with the NOE interactions from H-1' (δ_{H} 4.37) to H-3' (δ_{H} 3.27) and H-5' (δ_{H} 3.02) indicated axial orientation of H-1', H-3', H-4', and H-5', while H-2' was in equatorial orientation. Acidic hydrolysis²² of **1** resulted in the generation of a sugar, which was identical to D-mannose based on the comparison of its HPLC retention time, specific rotation and NMR data with those of authentic sample. The linkage of sugar to C-12 of the tricyclic nucleus through an ether bond was determined by the HMBC interaction between H₂-12 and C-1' (δ_{C} 101.9). The NOE interactions from H₃-13 to H-11, H₂-12 and H_b-7, in association with the NOE relationship between H₃-14 and H_a-7 (Fig. 3) indicated the *trans* junction of rings A and B and *cis* junction of rings B and C, while H₃-13 and H₃-14 were in opposite faces.

The molecular formula of chartarene B (**2**) was determined as C₁₆H₂₆O₄ based on the HRESIMS and NMR data (Table 1). Analyses of 2D NMR data (COSY, HMQC, and HMBC) established the planar structure of **2** possessing a tricyclic nucleus, which was the same as that of **1** with the exception of lack of

sugar moiety and the presence of a methoxy group at ring C. The COSY correlations from H₂-3 (δ_{H} 1.47, 2.08) to H-2 (δ_{H} 3.48) and H-4 (δ_{H} 3.89) in association with the HMBC correlations from H₂-12 (δ_{H} 3.41, 3.52) to C-1 (δ_{C} 91.2), C-2 (δ_{C} 85.7) and C-5 (δ_{C} 57.6) and the HMQC correlations between H-2/C-2 and H-4/C-4 (δ_{C} 69.2) indicated the substitution of oxygen atom at C-2 and C-4. In addition, the HMBC correlation between H-2 and a methoxy carbon at δ_{C} 58.2 clarified a methoxy substitution at C-2. Thus, C-4 was located with a hydroxy group, and this assignment was supported by the COSY relationship between H-4 and OH-4 (δ_{H} 4.50). The NOE interactions between H-2/H-4 and H₃-14/H-11, and from H₂-12 to OMe and H₃-13 (Fig. 3), determined the *cis* fusion of rings A/B and B/C, while H-2 and H-4 were oriented in the same face as H₃-14.

The HRESIMS and NMR data indicated the molecular formula of chartarene C (**3**) to be C₁₅H₂₂O₄, requiring five degrees of unsaturation. The 1D and 2D NMR data established a sambucinol-type analogue with the planer structure of **3** to be related to loukacinal A.⁵ The distinction was attributed to C-8, where a methylene group of **3** replacing a ketone of loukacinal A was evident from H₂-8 (δ_{H} 1.92, 2.10) correlated to the olefinic carbons C-9 (δ_{C} 143.9) and C-10 (δ_{C} 117.5) in the HMBC spectrum. The similar NOE interactions between **3** and loukacinal A indicated both compounds possessing the same configurations. These assignments were confirmed by the analyses of the X-ray diffraction data using the Flack parameter (Fig. 4).

The molecular formula of chartarene D (**4**) was determined as C₂₉H₃₆O₈ by HRESIMS (m/z 535.23084 [M + Na]⁺) and NMR data. Analyses of the 2D NMR data indicated the structure of **4** as consisting of three building blocks (units A–C). Unit A was

Fig. 4 X-ray structures of **3**, **6**, and **14**.

identical to verrucarol²³ based on comparable NMR data (Table 2) in association with the HMBC interactions from H₃-15 (δ_{H} 1.66, s) to C-8 (δ_{C} 27.6) and both olefinic carbons C-9 (δ_{C} 139.2) and C-10 (δ_{C} 119.6), H₃-13 (δ_{H} 0.69, s) to C-1 (δ_{C} 65.8), C-4 (δ_{C} 75.6), C-5 (δ_{C} 48.2), and C-6 (δ_{C} 42.8), as well as the epoxy protons H₂-12 (δ_{H} 2.80, 3.07) to C-1, C-2 (δ_{C} 78.4) and C-5. Unit B was determined as a 5-oxy-3-methyl-2-pentenoic unit, based on the HMBC interactions from the methyl protons H₃-6' (δ_{H} 2.13, s) to C-2' (δ_{C} 117.3), C-3' (δ_{C} 157.6), and C-4' (δ_{C} 41.1), olefinic proton H-2' (δ_{H} 5.79, s) to the carbonyl carbons C-1' (δ_{C} 165.7) and C-4', in addition to the COSY relationship between H₂-4' and the oxymethylene H₂-5' (δ_{H} 3.77, 4.17). Subsequently, unit C was determined as a 6-oxygenated 7-oxo-3,5-octadienoic acid, based on the COSY correlations from H₂-2'' (δ_{H} 3.16, 3.35) to H-5'' (δ_{H} 6.75, d, J = 10.0 Hz), in association with the HMBC interactions from H₃-8'' (δ_{H} 2.27, s) to a ketone C-7'' (δ_{C} 195.3) and an olefinic carbon C-6'' (δ_{C} 150.5) and from H-3'' and H₂-2'' to a carbonyl carbon C-1''. The linkage of units A and B by an ester bond across C-14 and C-1' was deduced by the HMBC interaction between H₂-14 (δ_{H} 3.83, 4.28) and C-1', while the conjunction of units B and C through an ester bond across C-4 and C-1'' was indicated by the HMBC correlation between H-4 (δ_{H} 5.98) and C-1'' (δ_{C} 170.1) (Fig. 2). The connection of units B and C with an ether bond between C-5' and C-6'' was deduced by the HMBC relationship between H₂-5' (δ_{H} 3.77, 4.17) and C-

6''. Thus, **4** was established as a roridoid-type analogue, structurally related to roridin E with the migration of the olefinic bonds to C-3''/C-4'' and C-5''/C-6'' and the substitution of a ketone at C-7''. The NOE interaction between H-2' and H₂-4' in association with the chemical shift of the methyl carbon C-6' (δ_{C} 18.3, <20 ppm) determined 2'*E* geometry. The $J_{\text{H-3''/H-4''}}$ value (12.0 Hz) and the NOE interaction between H₃-8'' and H-5'' confirmed 3''*Z* and 5''*Z* geometries. Acidic hydrolysis of **4** produced a product which was identical to verrucarol, confirming the stereogenic centers in moiety A of **4** to be the same as those of verrucarol.

Moreover, the known compounds were identical to mytoxin A (**5**),²⁴ satratoxin G (**6**),²⁵ roridin L-2 (**7**),²⁶ satratoxin H (**8**),²⁷ muconomycin B (**9**),²⁸ roridin E (**10**),²⁹ verrol (**11**),³⁰ trichoderma-dienediol B (**12**),³¹ isotrichoverrol B (**13**),³² 2,4,12-trihydroxyapotrictiothecene (**14**), and trichodermol (**15**),³³ based on the comparison of their NMR and MS data in association with specific rotation with those reported in the literature. 2,4,12-Trihydroxyapotrictiothecene (**14**) was isolated from a microorganism for the first time, while the absolute configurations of **14** and satratoxin G (**6**) were uncertain in the literature. In the present work, the absolute configurations of satratoxin G (**6**) and 2,4,12-trihydroxyapotrictiothecene (**14**) were established by the analyses of the X-ray diffraction data using Flack parameters (Fig. 4).

Table 2 ^1H NMR and ^{13}C NMR data and key HMBC correlations of **4** (DMSO- d_6)

4			
	δ_{C}	δ_{H}	HMBC
1	65.8 C		
2	78.4 CH	3.68, d ($J = 4.0$ Hz)	C-1, C-4, C-5, C-11
3	42.6 CH ₂	1.88, m; 2.50 m	
4	75.6 CH	5.98, dd ($J = 2.4, 6.4$ Hz)	C-3, C-5, C-6, C-1''
5	48.2 C		
6	42.8 C		
7	21.2 CH ₂	1.91, m; 1.94, m	
8	27.6 CH ₂	1.98, m; 2.00, m	
9	139.2 C		
10	119.6 CH	5.37, d ($J = 3.2$ Hz)	C-6, C-8, C-11
11	66.6 CH	3.87, d ($J = 3.2$ Hz)	C-6, C-9, C-10, C-2
12	47.7 CH ₂	2.80, d ($J = 3.6$ Hz); 3.07, d ($J = 3.6$ Hz)	C-1, C-2, C-5
13	7.25 CH ₃	0.69, s	C-1, C-3, C-4, C-5
14	63.7 CH ₂	3.83, d ($J = 12.0$ Hz); 4.28, d ($J = 12.0$ Hz)	C-5, C-6, C-7, C-11, C-1'
15	23.3 CH ₃	1.66, s	C-8, C-9, C-10
1'	165.7 C		
2'	117.3 CH	5.79, s	C-1', C-4', C-6'
3'	157.6 C		
4'	41.1 CH ₂	2.40, m; 2.50, m	
5'	68.5 CH ₂	3.77, m; 4.17, m	C-3', C-4', C-6''
6'	18.3 CH ₃	2.13, s	C-3', C-4', C-5
1''	170.1 C		
2''	36.3 CH ₂	3.16, dd ($J = 3.0, 12.0$ Hz), 3.35, dd ($J = 3.0, 12.0$ Hz)	C-1'', C-4''
3''	132.9 CH	6.18, dt ($J = 3.0, 16.0$ Hz)	C-1'', C-5''
4''	124.9 CH	6.56, dd ($J = 10.0, 16.0$ Hz)	C-2'', C-6''
5''	126.5 CH	6.75, d ($J = 10.0$ Hz)	C-3'', C-7''
6''	150.5 C		
7''	195.3 C		
8''	26.6 CH ₃	2.27, s	C-6'', C-7''

3.2. Bioassay

Compounds **1–15** were tested against a panel of human tumor cell lines, including human colon carcinoma (HCT-116), human hepatocellular carcinoma (HepG2), gastric cancer (BGC-823), non-small-cell lung adenocarcinoma (NCI-H1655), and human ovarian cancer (A2780), by the MTT method.³⁴ As shown in Table 3, all compounds exhibited selective inhibition against the tumor cell lines, while compounds **5**, **6**, **8**, and **10** showed potent cytotoxic activities against the panel of tumor cell lines with IC₅₀ values less than 10 nM. Preliminary analyses of the structure–activity relationship revealed that the cytotoxic effects are related to the scaffolds and the substitution. Apotrichothecene-based analogues with a sugar moiety at C-12 and without hydroxy group at C-2 and C-4 (**1**) or with a methoxy group at C-2 (**2**) showed weaker cytotoxicity in comparison with the 2,4,12-trihydroxy analogue (**14**). For the trichodermol-type analogues, those with a macrocyclic ring along with a tetrahydropyran ring (**5**, **6**, **8**) exerted remarkable effects, whereas the analogues without a tetrahydropyran ring in the macrocyclic moiety (**4**, **9**) showed less cytotoxicity. However, compound **10** is an exception which showed IC₅₀ within 10 nM, while the structural distinction of **4** and **10** was attributed to the olefinic rearrangement and the substitution at C-7'' of the macrocyclic ring. Compounds **7** and **11–13** with a linear moiety at C-4 or C-14 had decreased inhibitory effects in comparison with **5**.

In order to gain an insight into the mechanism of the antitumor-active compounds, a panel of tumor growth-related tyrosine kinases including FGFR3 (fibroblast growth factor receptor 3), IGF1R (insulin-like growth factor 1 receptor), PDGFRb (β -type platelet-derived growth factor receptor), and TRKB (tropomyosin receptor kinase B) were selected for testing. The bioassay results revealed that most compounds exerted potent inhibitory activities (Table 4), except for **1** and **13** showing weak activity with IC₅₀ values of more than 20 μM .

FGF signaling plays a role in various aspects of cancer biology, involving proliferation, anti-apoptosis, drug resistance,

Table 3 Inhibitory effects of **1–15** against tumor cell lines

Compound	IC ₅₀ (μM)				
	HCT-116	HepG2	BGC-823	NCI-H1650	A2780
1	3.39 $\pm$ 0.01	3.95 $\pm$ 0.01	2.87 $\pm$ 0.02	>10	2.38 $\pm$ 0.02
2	5.58 $\pm$ 0.03	>10	>10	>10	>10
3	0.74 $\pm$ 0.02	2.09 $\pm$ 0.01	>10	2.58 $\pm$ 0.03	2.07 $\pm$ 0.02
4	1.48 $\pm$ 0.01	0.90 $\pm$ 0.02	0.68 $\pm$ 0.04	1.23 $\pm$ 0.02	0.69 $\pm$ 0.03
5	<0.01	<0.01	<0.01	<0.01	<0.01
6	<0.01	<0.01	<0.01	<0.01	<0.01
7	1.73 $\pm$ 0.03	1.2 $\pm$ 0.02	1.81 $\pm$ 0.04	2.36 $\pm$ 0.03	1.61 $\pm$ 0.01
8	<0.01	<0.01	<0.01	<0.01	<0.01
9	1.32 $\pm$ 0.03	0.81 $\pm$ 0.03	0.84 $\pm$ 0.02	0.86 $\pm$ 0.01	0.68 $\pm$ 0.02
10	<0.01	<0.01	<0.01	<0.01	<0.01
11	2.77 $\pm$ 0.04	1.45 $\pm$ 0.02	2.33 $\pm$ 0.01	2.68 $\pm$ 0.01	2.00 $\pm$ 0.03
12	1.65 $\pm$ 0.03	0.86 $\pm$ 0.05	0.81 $\pm$ 0.03	1.31 $\pm$ 0.01	0.68 $\pm$ 0.04
13	3.48 $\pm$ 0.06	2.62 $\pm$ 0.03	2.64 $\pm$ 0.04	2.36 $\pm$ 0.02	2.12 $\pm$ 0.01
14	0.87 $\pm$ 0.05	0.69 $\pm$ 0.04	0.65 $\pm$ 0.04	0.84 $\pm$ 0.07	0.69 $\pm$ 0.03
15	7.22 $\pm$ 0.04	3.69 $\pm$ 0.04	2.55 $\pm$ 0.05	2.68 $\pm$ 0.06	2.68 $\pm$ 0.03
Taxol	0.03	0.01	0.01	0.04	0.01

Table 4 Inhibitory effects of 1–15 against tumor-related kinases

Compound	IC ₅₀ (μM)				
	FGFR3	IGF1R	PDGFRb	TRKB	WT
1	>25	>25	>25	>25	>25
2	2.4	6.9	10.4	7.0	12.9
3	1.1	3.0	5.3	2.7	6.3
4	0.1	0.1	0.8	0.7	0.7
5	<0.1	<0.1	<0.1	<0.1	<0.1
6	0.1	0.1	0.5	0.2	0.9
7	0.4	0.5	2.3	1.9	1.7
8	<0.1	<0.1	<0.1	<0.1	0.1
9	0.3	0.4	1.2	0.7	1.5
10	0.4	0.4	1.4	1.0	2.1
11	0.1	0.2	0.7	0.4	0.9
12	0.5	0.7	1.9	1.0	1.9
13	24.0	>25	>25	>25	>25
14	0.5	1.0	2.1	1.0	2.2
15	0.9	0.8	3.1	1.8	3.0

angiogenesis, EMT, and invasion; thus FGFR-targeted therapeutics is an active topic in the field of clinical oncology.^{35,36} IGF1R regulates the tumor microenvironment to promote cancer progression and metastasis,^{37,38} while PDGFR inhibition is an antiangiogenic approach potentially affecting all solid tumors due to tumor vasculature having a pericyte coverage.^{39,40} Meanwhile, high levels of TrkB are correlated with poor patient prognosis in neuroblastomas and ovarian, pancreatic, colon, prostate, and gastric cancers, while TrkB is overexpressed in ovarian adenocarcinoma metastases compared with primary lesions.^{41,42} The potent inhibition toward the spectrum of tyrosine kinases suggested that the antitumor effects of the trichothecene-type derivatives were mediated by multiple targets.

4. Conclusion

Trichothecene-type sesquiterpenoids are frequently found in *Stachybotrys* species in different terrestrial localities, while the unique scaffold of trichothecenes may be considered as chemotaxonomic markers. This work firstly reported the sponge-derived *Stachybotrys chartarum* to be a new fungal strain of functionalized trichothecenes. Trichothecene with a sugar linkage such as **1** was found from nature for the first time. The potent cytotoxic effects of the isolated compounds against a panel of tumor cell lines are induced by the inhibition of the multiple kinase targets FGFR3, IGF1R, PDGFRb, and TRKB. These findings provided additional data indicating that trichothecenes are promising kinase inhibitors for the development of antitumor leads.

Acknowledgements

This work was supported by grants of National High Technology and Science 973 program (2015CB755906), NSFC (81630089, 41376127) and NSFC-Shangdong Joint Fund for Marine Science (U1406402).

References

- 1 K. F. Nielsen, T. Grafenhan, D. Zafari and U. Thrane, *J. Agric. Food Chem.*, 2005, **53**, 8190–8196.
- 2 M. Namikoshi, K. Akano, S. Meguro, I. Kasuga, Y. Mine, T. Takahashi and H. Kobayashi, *J. Nat. Prod.*, 2001, **64**, 396–398.
- 3 T. Lin, G. Wang, Y. Zhou, D. Zeng, X. Liu, R. Ding, X. Jiang, D. Zhu, W. Shan and H. Chen, *J. Agric. Food Chem.*, 2014, **62**, 5993–6000.
- 4 M. P. Carvalho, H. Weich and W. R. Abraham, *Curr. Med. Chem.*, 2016, **23**, 23–35.
- 5 A. Loukaci, O. Kayser, K. U. Bindseil, K. Siems, J. Frevert and P. M. Abreu, *J. Nat. Prod.*, 2000, **63**, 52–56.
- 6 W. O. Godtfredsen and S. Vangedal, *Acta Chem. Scand.*, 1965, **19**, 1088–1102.
- 7 L. H. Senter, D. R. Sanson, D. G. Corley, M. S. Tempesta, A. A. Rottinghaus and G. E. Rottinghaus, *Mycopathologia*, 1991, **113**, 127–131.
- 8 S. P. McCormick, T. Kato, C. M. Maragos, M. Busman, V. M. Lattanzio, G. Galaverna, C. Dall'Asta, D. Crich, N. P. Price and C. P. Kurtzman, *J. Agric. Food Chem.*, 2015, **63**, 731–738.
- 9 T. Suzuki and Y. Iwahashi, *Toxins*, 2014, **6**, 453–463.
- 10 H. K. Abbas, T. Yoshizawa and W. T. Shier, *Toxicon*, 2013, **74**, 68–75.
- 11 J. W. He, G. S. Bondy, T. Zhou, D. Caldwell, G. J. Boland and P. M. Scott, *Food Chem. Toxicol.*, 2015, **84**, 250–259.
- 12 C. Arunachalam and F. M. Doohan, *Toxicol. Lett.*, 2013, **217**, 149–158.
- 13 L. O. Zamir, A. Nikolakakis, F. Sauriol and O. Mamer, *J. Agric. Food Chem.*, 1999, **47**, 1823–1835.
- 14 J. Merhej, F. Richard-Forget and C. Barreau, *Appl. Microbiol. Biotechnol.*, 2011, **91**, 519–528.
- 15 C. H. Diggs, M. J. Scoltock and P. H. Wiernik, *Cancer Clin. Trials*, 1978, **1**, 297–299.
- 16 D. W. Anderson, R. M. Black, C. G. Lee, C. Pottage, R. L. Rickard, M. S. Sandford, T. D. Webber and N. E. Williams, *J. Med. Chem.*, 1989, **32**, 555–562.
- 17 W. Ye, Y. Chen, H. Li, W. Zhang, H. Liu, Z. Sun, T. Liu and S. Li, *Molecules*, 2016, **21**(781), 1–11.
- 18 B. B. Jarvis, J. O. Midiwo and E. P. Mazzola, *J. Med. Chem.*, 1984, **27**, 239–244.
- 19 K. Konishi, A. Iida, M. Kaneko, K. Tomioka, H. Tokuda, H. Nishino and Y. Kumeda, *Bioorg. Med. Chem.*, 2003, **11**, 2511–2518.
- 20 L. O. Zamir, K. A. Devor, A. Nikolakakis, Y. Nadeau and F. Sauriol, *Tetrahedron Lett.*, 1992, **33**, 5181–5184.
- 21 L. O. Zamir, K. A. Devor, Y. Nadeau and F. Sauriol, *J. Biol. Chem.*, 1987, **262**, 15354–15358.
- 22 S. G. Ma, Y. C. Hu, S. S. Yu, Y. Zhang, X. G. Chen, J. Liu and Y. X. Liu, *J. Nat. Prod.*, 2008, **71**, 41–46.
- 23 J. Gutzwiller and C. Tamm, *Helv. Chim. Acta*, 1963, **46**, 1786–1790.
- 24 B. B. Jarvis, F. T. Comezoglu, Y. W. Lee, J. L. Flippen-Anderson, R. D. Gilardi and C. F. George, *Bull. Soc. Chim. Belg.*, 1986, **95**, 681–697.

- 25 R. M. Eppley, E. P. Mazzola, M. E. Stack and P. A. Dreifuss, *J. Org. Chem.*, 1980, **45**, 2522–2523.
- 26 R. J. Bloem, T. A. Smitka, R. H. Bunge, J. C. French and E. P. Mazzola, *Tetrahedron Lett.*, 1983, **24**, 249–252.
- 27 R. M. Eppley, E. P. Mazzola, R. J. Highet and W. J. Bailey, *J. Org. Chem.*, 1977, **42**, 240–243.
- 28 J. S. Vittimberga and B. M. Vittimberga, *J. Org. Chem.*, 1965, **30**, 746–748.
- 29 P. Traxler, W. Zuercher and C. Tamm, *Helv. Chim. Acta*, 1970, **53**, 2071–2085.
- 30 B. B. Jarvis, V. M. Vrudhula, J. O. Midiwo and E. P. Mazzola, *J. Org. Chem.*, 1983, **48**, 2576–2578.
- 31 R. Ren, C. Chen, X. Liu, H. Ge, R. Tan and R. Jiao, *Helv. Chim. Acta*, 2015, **98**, 1435–1441.
- 32 B. B. Jarvis, S. Wang and H. L. Ammon, *J. Nat. Prod.*, 1996, **59**, 254–261.
- 33 T. A. Smitka, R. H. Bunge, R. J. Bloem and J. C. French, *J. Antibiot.*, 1984, **37**, 823–828.
- 34 J. B. Burton, *Methods Mol. Med.*, 2005, **110**, 69–78.
- 35 M. Katoh and H. Nakagama, *Med. Res. Rev.*, 2014, **34**, 280–300.
- 36 P. S. Lee and A. A. Secord, *Cancer Treat. Rev.*, 2014, **40**, 507–512.
- 37 H. Werner and C. T. Roberts Jr, *Genes, Chromosomes Cancer*, 2003, **36**, 113–120.
- 38 D. C. Yang, R. L. Elliott and J. F. Head, *Expert Opin. Ther. Targets*, 2002, **6**, 375–385.
- 39 J. S. Huang, S. S. Huang, B. Kennedy and T. F. Deuel, *J. Biol. Chem.*, 1982, **257**, 8130–8136.
- 40 H. N. Antoniades, *Baillieres Clin. Endocrinol. Metabol.*, 1991, **5**, 595–613.
- 41 H. Dawson, S. Grundmann, V. H. Koelzer, J. A. Galván, R. Kirsch, E. Karamitopoulou, A. Lugli, D. Inderbitzin and I. Zlobec, *Histopathology*, 2015, **66**, 715–725.
- 42 K. W. Sinkevicius, C. Kriegel, K. J. Bellaria, J. Lee, A. N. Lau, K. T. Leeman, P. Zhou, A. M. Beede, C. M. Fillmore, D. Caswell, J. Barrios, K. K. Wong, L. M. Sholl, T. M. Schlaeger, R. T. Bronson, L. R. Chirieac, M. M. Winslow, M. C. Haigis and C. F. Kim, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 10299–10304.